 Home > Medical News > Latest Medical News > Inhibition of the RAS pathway can also affect protein degradation and the initial clinical results of innovative therapies for fatal brain cancer are positive

Inhibition of the RAS pathway can also affect protein degradation and the initial clinical results of innovative therapies for fatal brain cancer are positive

 Last Update: 2021-11-13
 Source: Internet
 Author: User

Tags

rituximab mechanism action

pharmaceutical oncology

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 4, 2021, Chimerix announced that ONC201, an investigational therapy with a dual mechanism of action, has achieved positive top-line results in clinical trials for the treatment of recurrent gliomas

ONC201 targets DRD2 and ClpP at the same time, blocking DRD2 can inhibit the RAS signaling pathway, and activating ClpP can promote the degradation of proteins in the mitochondria of cells that are related to the survival of cancer cells

▲The mechanism of ONC201 (picture source: reference [2])

The 50 patients whose efficacy can be evaluated in this trial have diffuse midline gliomas, which carry the H3 K27M mutation.

In terms of safety, the complete safety data collection and analysis of the cohort are in progress, and one serious adverse event was attributed to ONC201

"For these patients who do not have effective systemic treatment options, these data are exciting

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Courier's inhibition of the RAS pathway can also affect protein degradation, and initial clinical results of innovative therapies for fatal brain cancer are positive

11-13

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Inhibition of the RAS pathway can also affect protein degradation and the initial clinical results of innovative therapies for fatal brain cancer are positive

Related Articles

Courier's inhibition of the RAS pathway can also affect protein degradation, and initial clinical results of innovative therapies for fatal brain cancer are positive